PSA (Prostate-Specific Antigen) clinical trials
37 active trials name this biomarker in their eligibility criteria (recorded in the registry as “KLK3 Gene”) . Describe your situation to see which ones you may be eligible for.
- The SUGAR Study; SBRT and Relugolix) for Prostate Cancer
- Adenosine Signaling Modulation and Immune Checkpoint Inhibition With Hormone Sensitive Oligometastatic Prostate Cancer
- A Study of Pasritamig (JNJ-78278343) in Combination With JNJ-86974680 for Treatment of Prostate Cancer
- Safety and Efficacy of 21 Gy, 23 Gy and 25 Gy for High Dose Rate (HDR) Prostate Brachytherapy
- A Study of Pasritamig (JNJ-78278343) in Combination With Other Agents for Metastatic Prostate Cancer
- A Study to Assess BMS-986460 in Participants With Metastatic Castration-resistant Prostate Cancer
- Impact of Anti-inflammatory Medications in Patients With Elevated Serum Prostate-specific Antigen
- Reduction of Gastrointestinal Toxicity in Prostate Cancer by Proton Spot Placement
- A Trial to Find Out if REGN4336 is Safe and How Well it Works Alone and in Combination With Cemiplimab or REGN5678 for Adult Participants With Advanced Prostate Cancer
- Phase II Trial of PSA Response-based Androgen Deprivation Therapy and Nodal Coverage for Prostate Cancer Early Salvage Radiotherapy (RANGER)
- Single-Port Transvesical Partial Prostatectomy Versus High Intensity Focused Ultrasound
- 5-Alpha Reductase 2 as a Marker of Resistance to 5ARI Therapy
- ProACT Post-Approval Study
- Trial of Curcumin to Prevent Progression of Low-risk Prostate Cancer Under Active Surveillance
- The University of Miami Adapt (UAdapt) Trial
- A Study of Valemetostat (DS-3201b) in Combination With Darolutamide in Metastatic Castration Resistant Prostate Cancer (mCRPC)
- MDRT in Prostate Cancer Treated With Long-term Androgen Deprivation Therapy in the STAMPEDE Trial (METANOVA)
- Anti-inflammatory Drugs and Serum Prostate-Specific Antigen Test
- COAST Therapy in Advanced Solid Tumors and Prostate Cancer
- Tesamorelin as an Adjunct to Exercise for Improving Physical Function in HIV
- Improving Cryoablation Efficacy With BARRigel Rectal Spacing (ICE-BARR)
- Barrigel® PPRT (Post-Prostatectomy Radiation Therapy) Trial
- AI Algorithm-Informed Biopsy for Prostate Cancer Detection With Indeterminate and Low-Risk Prostate MRI Lesions
- Evaluation of Prostate Specific Membrane Antigen Positron Emission Tomography-Computed Tomography in Active Surveillance for Prostate CancEr
- Diagnostic Utility of rhPSMA-7.3 (18F) PET/CT in Men With Prostate Cancer on Active Surveillance
- PET Scan Study to Detect Prostate Cancer in Patients with Early PSA Recurrence
- Investigation of Impact of AI on Prostate Cancer Workflow
- An Investigational Scan (rhPSMA-7.3 PET/CT) for Detecting Biochemically Recurrent Prostate Cancer, ENLIGHTEN Trial
- PSMA PET Combined With MRI for the Detection of PCa
- Prostate Cancer Risk Identification in a Multi-Ethnic Cohort: a Prospective US-based Multi-center Validation Study of Proclarix
- Plasma exoRNA-Based Liquid Biopsy to Diagnose Clinically Significant Prostate Cancer
- Prostate Cancer Postoperative Stereotactic Body Radiotherapy With Adaptive Technology for Minimizing Toxicity
- Rectal Spacers Use in Prostate Cancer Radiation Therapy
- Evaluating Treatment Outcomes Using Darolutamide and Androgen Deprivation Therapy in Patients With Metastatic Hormone-Sensitive Prostate Cancer.
- Ambulatory Blood Pressure Monitoring (ABPM) Study in Hypogonadal Men
- Androgen Deprivation, With or Without pTVG-AR, and With or Without T-Cell Checkpoint Blockade, in Patients With Newly Diagnosed, High-Risk Prostate Cancer
- Role of rhPSMA-7.3 PET/CT Imaging in Men With High-Risk Prostate Cancer Following Conventional Imaging and Associated Changes in Medical Management
Guides for people searching for a trial
- How your biomarkers decide which trials you qualify forEGFR, HER2, BRAF, PD-L1 and the rest — what they are and why they increasingly gate access.
- Why people get turned down — and what to do nextWhat eligibility criteria are for, what keeps people out, and where to go when the first door closes.
- How to search for a trial without losing your mindWhere to look, what to gather first, and how to read what you find.
- What Phase 1, 2 and 3 actually mean for youWhat each phase is testing, and how to weigh an early-phase trial against a later one.
- 10 questions to ask before you say yesTreatment, time, cost, safety and your rights. Worth bringing to a screening visit.
- You matched with a trial. What happens now?Phone screens, the screening visit, informed consent, and day one.
Showing active trials that name “KLK3 Gene” in their eligibility criteria, at any level. Eligibility shown on each trial is an estimate — the trial's study team makes the final decision.